arrow_back Back to App

Securing Military Drug Supply: Assessing Foreign Pharmaceutical Risk.

This law aims to strengthen the security of essential drug supplies for the Department of Defense (DoD). It mandates the military to prepare a detailed report on its reliance on foreign suppliers for pharmaceutical ingredients, particularly those from high-risk countries. While directly focused on the military, the goal is to enhance national pharmaceutical security, indirectly contributing to supply stability during crises.
Key points
Requires a report analyzing the extent to which the Department of Defense relies on foreign suppliers for key pharmaceutical ingredients.
Mandates updating risk management guidelines for the military drug supply chain to reduce vulnerability to disruptions.
The DoD must rely on the Food and Drug Administration (FDA) determinations regarding drug components.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_4635
Sponsor: Sen. Peters, Gary C. [D-MI]
Process start date: 2024-07-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmaceutical Risk Assessment and Mitigation Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_4635.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-07-08.

What are the main provisions?

Key points include:

  • Requires a report analyzing the extent to which the Department of Defense relies on foreign suppliers for key pharmaceutical ingredients.
  • Mandates updating risk management guidelines for the military drug supply chain to reduce vulnerability to disruptions.
  • The DoD must rely on the Food and Drug Administration (FDA) determinations regarding drug components.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Peters, Gary C. [D-MI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Security Health